KR102673967B1 - Mdm2-p53 상호작용의 아이소인돌린온 저해제 및 이를 제조하는 방법 - Google Patents

Mdm2-p53 상호작용의 아이소인돌린온 저해제 및 이를 제조하는 방법 Download PDF

Info

Publication number
KR102673967B1
KR102673967B1 KR1020197030377A KR20197030377A KR102673967B1 KR 102673967 B1 KR102673967 B1 KR 102673967B1 KR 1020197030377 A KR1020197030377 A KR 1020197030377A KR 20197030377 A KR20197030377 A KR 20197030377A KR 102673967 B1 KR102673967 B1 KR 102673967B1
Authority
KR
South Korea
Prior art keywords
alkyl
formula
compound
ring members
chlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197030377A
Other languages
English (en)
Korean (ko)
Other versions
KR20190133190A (ko
Inventor
스티븐 하워드
벤자민 데이빗 콘스
데니스 제프리 데이빗 세인트
샬럿 메리 그리피스-존스
스티븐 더글라스 히스콕
리안 사라 홀베이
앨런 리처드 번스
데이빗 커즌
한나 루이즈 덱스터
기욤 프랑스와 파라
존 폴 왓츠
로버트 쥬얼
제니퍼 안 스톡웰
킴 루이즈 허스트
이사벨 앤 르마송
데이빗 존 내쉬
제임스 다니엘 오스본
요나스 칼레야 프리데
니콜라스 폴 리처즈
아론 마이클 뒤마
브라이언 크리스토퍼 비숍
데이빗 패리-존스
제레미 피터 스콧
메나크쉬 순다람 샨무감
피터 리처드 뮬런스
데이빗 찰스 라스베리
대런 제임스 딕슨
매튜 제임스 곤트
Original Assignee
아스텍스 테라퓨틱스 리미티드
캔써 리서치 테크놀로지 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스텍스 테라퓨틱스 리미티드, 캔써 리서치 테크놀로지 리미티드 filed Critical 아스텍스 테라퓨틱스 리미티드
Publication of KR20190133190A publication Critical patent/KR20190133190A/ko
Application granted granted Critical
Publication of KR102673967B1 publication Critical patent/KR102673967B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020197030377A 2017-03-28 2018-03-28 Mdm2-p53 상호작용의 아이소인돌린온 저해제 및 이를 제조하는 방법 Active KR102673967B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1704965.1 2017-03-28
GBGB1704965.1A GB201704965D0 (en) 2017-03-28 2017-03-28 Pharmaceutical compounds
PCT/GB2018/050845 WO2018178691A1 (en) 2017-03-28 2018-03-28 Isoindolinone inhibitors of the mdm2-p53 interaction and process for making them

Publications (2)

Publication Number Publication Date
KR20190133190A KR20190133190A (ko) 2019-12-02
KR102673967B1 true KR102673967B1 (ko) 2024-06-12

Family

ID=58687834

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197030377A Active KR102673967B1 (ko) 2017-03-28 2018-03-28 Mdm2-p53 상호작용의 아이소인돌린온 저해제 및 이를 제조하는 방법

Country Status (7)

Country Link
US (3) US11603367B2 (https=)
EP (1) EP3601272A1 (https=)
JP (1) JP7495790B2 (https=)
KR (1) KR102673967B1 (https=)
CN (1) CN110678462B (https=)
GB (1) GB201704965D0 (https=)
WO (1) WO2018178691A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) * 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
CN113453678A (zh) * 2018-11-26 2021-09-28 德彪药业国际股份公司 Hiv感染的联合治疗
CN109897069B (zh) * 2019-02-12 2021-08-20 华东师范大学 一种3,3-二取代吲哚啉酮及其衍生物及其合成方法和应用
CN110845288B (zh) * 2019-11-28 2022-07-19 浙江工业大学 一种手性β-氨基醛类化合物的不对称合成方法
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
CN111057128B (zh) * 2019-12-25 2023-05-16 哈尔滨师范大学 一种含硫的异吲哚酮并环肽衍生物及其制备方法
EP4204812A2 (en) 2020-08-27 2023-07-05 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using mdm2 antagonists
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
TW202540077A (zh) * 2023-11-16 2025-10-16 日商大塚製藥股份有限公司 具有抗癌活性之mdm2-p53交互作用的異吲哚啉酮抑制劑的中間體的製造方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009156735A2 (en) 2008-06-25 2009-12-30 Cancer Research Technology Limited New therapeutic agents
WO2017055860A1 (en) 2015-09-29 2017-04-06 Astex Therapeutics Limited Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH374071A (de) 1959-04-30 1963-12-31 Geigy Ag J R Verfahren zur Herstellung von neuen Isoindolinderivaten
US3466298A (en) 1967-03-14 1969-09-09 American Home Prod Process for the preparation of 2-(2-aminoethyl)isoindolines
US3763178A (en) 1968-09-05 1973-10-02 American Home Prod Imidazolinyl phenyl carbonyl acid addition salts and related compounds
GB1325066A (en) 1970-02-12 1973-08-01 American Home Prod Phthalimidine compounds
AR203996A1 (es) 1972-03-16 1975-11-12 Rhone Poulenc Sa Procedimiento para preparar derivados de(hidroxi-2-amino-3-propoxi)-3-isoindolinona-1
FR2217000B1 (https=) 1973-02-08 1976-04-09 Rhone Poulenc Ind
GB1601701A (en) 1977-07-22 1981-11-04 Delmar Chem Production of heterocyclic benzamide compounds
US4200759A (en) 1978-07-20 1980-04-29 Delmar Chemicals, Limited Preparation of imidazo[2,1-a]isoindole compounds
US4244966A (en) 1979-09-24 1981-01-13 American Home Products Corporation 1,3-Dihydro-3-(2-hydroxy-, 2-bromo- or 2-chloroethyl)-2H-isoindol-1-one derivatives
US4331600A (en) 1980-10-31 1982-05-25 Usv Pharmaceutical Corporation Intermediates for the synthesis of phthalimidines
US4312809A (en) 1980-10-31 1982-01-26 E. R. Squibb & Sons, Inc. Lactam derivatives of mercaptoacylamino acids
FR2533563A1 (fr) 1982-09-23 1984-03-30 Adir Nouveaux derives de la sulfonyluree, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
HU212435B (en) 1990-06-07 1996-06-28 Sandoz Ag Herbicidal compositions containing substituted phthalides and heterocyclic phthalides as active ingredient and process for preparation of their active ingredients.
TW448172B (en) 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
DE19807423A1 (de) 1998-02-21 1999-08-26 Hoechst Marion Roussel De Gmbh Subustituierte Isoindolone, ihre Herstellung und ihre Verwendung in Arzneimitteln
CA2380389A1 (en) 1999-07-26 2001-02-01 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
WO2001032928A2 (en) 1999-11-05 2001-05-10 Phase-1 Molecular Toxicology Methods of determining individual hypersensitivity to an agent
DE10134482A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte Isoindole und ihre Verwendung
PL370823A1 (en) 2001-12-18 2005-05-30 F.Hoffmann-La Roche Ag Cis-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors
FR2840302B1 (fr) 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
WO2004048332A1 (ja) 2002-11-26 2004-06-10 Maruishi Pharmaceutical Co., Ltd. イソインドリン誘導体
JP2004217591A (ja) * 2003-01-16 2004-08-05 Dai Ichi Seiyaku Co Ltd シス選択的フルオロシクロプロパン誘導体の製造方法
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
JP2005255660A (ja) 2004-03-10 2005-09-22 Katsuhiko Tomooka 多官能基を有するラクタム類とその製法
WO2005095341A1 (ja) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. 含窒素複素環化合物
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
KR100944301B1 (ko) 2005-02-22 2010-02-24 더 리젠츠 오브 더 유니버시티 오브 미시간 Mdm2의 소분자 억제제 및 이의 용도
US7705021B2 (en) * 2005-05-02 2010-04-27 Fox Chase Cancer Center Isoindolone compounds, compositions containing the same, and methods of use thereof for the treatment of viral infections related to the etiology of cancer
JP5031745B2 (ja) 2005-08-12 2012-09-26 アストラゼネカ アクチボラグ 代謝型グルタミン酸受容体増強性イソインドロン
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
JPWO2008047831A1 (ja) 2006-10-17 2010-02-25 協和発酵キリン株式会社 Jak阻害剤
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
KR20100033981A (ko) 2007-06-03 2010-03-31 벤더르빌트 유니버시티 벤즈아미드 대사성 글루타민산염 수용체5 양성 알로스테릭 조절자 및 이의 제조 및 사용방법
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
MY160424A (en) 2008-09-18 2017-03-15 Hoffmann La Roche Substituted pyrrolidine-2-carboxyamides.
UA107814C2 (uk) 2009-11-12 2015-02-25 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Спірооксіндольні антагоністи мdм2
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
SG193002A1 (en) 2011-03-10 2013-09-30 Daiichi Sankyo Co Ltd Dispiropyrrolidine derivative
US8859586B2 (en) 2011-06-20 2014-10-14 Novartis Ag Cyclohexyl isoquinolinone compounds
WO2012175520A1 (en) 2011-06-20 2012-12-27 Novartis Ag Hydroxy substituted isoquinolinone derivatives
EP3431142B1 (en) 2011-08-30 2020-06-17 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
KR101401705B1 (ko) 2012-01-31 2014-06-27 울산대학교 산학협력단 로듐 촉매를 이용한 이소인돌린 유도체의 합성방법
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
HRP20200521T1 (hr) 2012-10-30 2020-08-07 Mei Pharma, Inc. Kombinacijske terapije za liječenje kemorezistentnih rakova
CA2902433A1 (en) 2013-03-01 2014-09-04 Astex Pharmaceuticals, Inc. Drug combinations
SG11201510816SA (en) 2013-07-03 2016-01-28 Hoffmann La Roche Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist
US20160333419A1 (en) 2014-01-14 2016-11-17 Daiichi Sankyo Company, Limited Gene signatures associated with sensitivity to mdm2 inhibitors
CA2945527C (en) 2014-04-17 2022-05-17 The Regents Of The University Of Michigan Mdm2 inhibitors and therapeutic methods using the same
JP2017532959A (ja) 2014-10-09 2017-11-09 第一三共株式会社 Mdm2阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム
EP3206697A2 (en) 2014-10-17 2017-08-23 Biomirna Holdings Ltd. Lung cancer diagnostics and therapeutics with mir-660
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
HUE068392T2 (hu) 2015-10-21 2024-12-28 Otsuka Pharma Co Ltd Benzolaktám vegyületek mint fehérje kináz gátlók
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) * 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
CA3050645A1 (en) 2018-07-27 2020-01-27 Ottawa Hospital Research Institute Treatment of acute myeloid leukemia
EP3814525A4 (en) 2019-02-24 2022-04-13 Ascentage Pharma (Suzhou) Co., Ltd. TREATMENT METHODS AND BIOMARKERS FOR MDM2 INHIBITORS
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
EP4204812A2 (en) 2020-08-27 2023-07-05 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using mdm2 antagonists
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009156735A2 (en) 2008-06-25 2009-12-30 Cancer Research Technology Limited New therapeutic agents
WO2017055860A1 (en) 2015-09-29 2017-04-06 Astex Therapeutics Limited Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity

Also Published As

Publication number Publication date
JP7495790B2 (ja) 2024-06-05
EP3601272A1 (en) 2020-02-05
WO2018178691A1 (en) 2018-10-04
US20230278989A1 (en) 2023-09-07
KR20190133190A (ko) 2019-12-02
GB201704965D0 (en) 2017-05-10
US11603367B2 (en) 2023-03-14
CN110678462B (zh) 2024-10-29
US12077526B2 (en) 2024-09-03
US20210101887A1 (en) 2021-04-08
JP2020515546A (ja) 2020-05-28
CN110678462A (zh) 2020-01-10
US20250074900A1 (en) 2025-03-06

Similar Documents

Publication Publication Date Title
AU2021202962C1 (en) Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity
KR102673967B1 (ko) Mdm2-p53 상호작용의 아이소인돌린온 저해제 및 이를 제조하는 방법
KR102743663B1 (ko) 항암 활성을 갖는 mdm2-p53 상호작용의 아이소인돌리논 저해제
HK40082646A (en) Intermediates of isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
HK40088238A (zh) 具有抗癌活性的mdm2-p53相互作用的异吲哚啉酮抑制剂
RU2794333C1 (ru) Изоиндолиноновые ингибиторы взаимодействия mdm2-p53, обладающие противораковой активностью
HK1250715B (en) Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
NZ740737B2 (en) Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
BR112018005936B1 (pt) Inibidores de isoindolinona da interação de mdm2-p53, composição farmacêutica, seus usos e processo para a preparação do composto

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191016

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210325

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230109

Patent event code: PE09021S01D

AMND Amendment
E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231115

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20240320

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20240215

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20230707

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210325

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240605

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240605

End annual number: 3

Start annual number: 1

PG1601 Publication of registration